Key result
Adiponectin was initially suggested as an independent predictor for cardiovascular risk in male cohorts, but this was not confirmed in subsequent studies including women and diverse populations.
Why the study?
Does adiponectin predict cardiovascular risk?
Does adiponectin predict cardiovascular risk?
The utility of adiponectin as an independent predictor of cardiovascular risk remains controversial, with conflicting evidence across different populations.
Adiponectin should not guide cardiovascular risk assessment; leaves open its predictive utility across populations.
Adiponectin is an endogenous insulin-sensitising and anti-inflammatory hormone, released by the adipose tissue. Because of its in vitro effects on endothelial cells, macrophages and vascular smooth muscle cells, adiponectin is thought to have anti-atherogenic properties. Moreover, findings from the Health Professionals Follow-up Studies and other cohort studies, mainly in male populations, suggest that adiponectin may be an independent predictor for cardiovascular risk. This, however, was not confirmed by subsequent studies that included female subjects, different ethnicities and patients with established coronary artery disease. The present article briefly summarises recent findings regarding the potential role of adiponectin as a predictor of risk and its biological role. Br J Diabetes Vasc Dis 2009;9: 150—154
No takes yet. Share an insight, caveat, or question.
Karastergiou et al. (2009) conducted a review in Cardiovascular risk. Adiponectin was evaluated on Cardiovascular risk. Adiponectin was initially suggested as an independent predictor for cardiovascular risk in male cohorts, but this was not confirmed in subsequent studies including women and diverse populations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: